A Randomized, Multicenter, Open Label Study Evaluating the Efficacy and Safety of Tailored Regimens With Peginterferon Alfa-2a Plus Ribavirin According Viral Kinetics for Genotype 1 Chronic Hepatitis C Patients
Phase of Trial: Phase IV
Latest Information Update: 03 Jan 2017
Price : $35 *
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TARGET-1
- 03 Jan 2017 Last checked against ClinicalTrials.gov record.
- 28 Dec 2016 Status changed from recruiting to completed.
- 12 Sep 2013 New trial record